BridgeBio Pharma, Inc.
BBIO
$38.34
$0.320.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.10% | 16.70% | 28.37% | 20.80% | -26.67% |
| Total Depreciation and Amortization | -10.75% | -6.45% | -4.20% | -2.75% | -0.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -82.33% | -122.21% | -151.02% | -112.79% | 1,218.60% |
| Change in Net Operating Assets | 174.90% | 533.62% | 893.89% | 433.40% | -3,065.05% |
| Cash from Operations | 17.00% | 1.33% | 9.26% | 14.65% | -49.54% |
| Capital Expenditure | 88.03% | 28.56% | 20.99% | 19.25% | 49.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 72.17% | 72.17% | 80.52% | 100.00% |
| Other Investing Activities | -44.63% | 10.77% | -11.89% | -64.56% | -79.93% |
| Cash from Investing | -43.50% | 12.49% | -11.26% | -65.01% | -80.27% |
| Total Debt Issued | 138.89% | -- | -- | -- | -- |
| Total Debt Repaid | 3.05% | -- | -- | -- | -2,210.93% |
| Issuance of Common Stock | -98.30% | -29.63% | -30.87% | 312.23% | 315.96% |
| Repurchase of Common Stock | -490.03% | -13.08% | -85.52% | -260.64% | -373.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -126.74% | -5,330.59% | -628.98% | -427.45% | -344.13% |
| Cash from Financing | -8.88% | 65.76% | -41.61% | 267.47% | 323.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.93% | 1,402.42% | -403.13% | 251.93% | -30.42% |